Age-Period-Cohort Analysis of Primary Bone Cancer Incidence Rates in the United States (1976–2005)

Background: Primary bone cancer comprises three major histologic types: osteosarcoma (OS), Ewing sarcoma (ES), and chondrosarcoma (CS). Given the limited knowledge about the etiology of primary bone cancer, we undertook an age-period-cohort (APC) analysis to determine whether incidence varied by birth cohort or calendar period. The purpose was to examine the temporal development of each bone cancer type and generate etiologic hypotheses via the observed birth cohort-related changes. Methods: An APC model was fitted to incidence data for U.S. whites for OS, ES, and CS obtained from nine registries of the Surveillance, Epidemiology, and End Results program, which covers about 10% of the U.S. population, 1976–2005. Results: The incidence of OS decreased between 1976 and 2005 among those aged over 60 years, a decline that occurred among patients with OS as their primary malignancy only. From 1986–1995 to 1996–2005, the incidence rate of CS among females of 20 to 69 years rose by about 50%, with rates increasing among consecutive cohorts born during 1935–1975. CS rates among males were stable, as were rates of ES. Conclusion: The risk reduction in OS as a primary malignancy at older ages could possibly be related to diminished exposure over time to bone-seeking radionuclides. The CS increase among females corresponds to birth cohorts with rising exposures to oral contraceptives and menopausal hormonal therapy. Impact: As the estrogen signaling pathway has been shown to stimulate proliferation of normal and malignant chondrocytes, estrogen exposure may increase the risk for CS. Further studies are warranted to clarify its possible etiological significance. Cancer Epidemiol Biomarkers Prev; 20(8); 1770–7. ©2011 AACR.

[1]  B. Alman,et al.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets , 2010, Nature Reviews Cancer.

[2]  L. Koniaris,et al.  Ewing sarcoma demonstrates racial disparities in incidence‐related and sex‐related differences in outcome , 2009, Cancer.

[3]  Lisa Mirabello,et al.  International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons , 2009, International journal of cancer.

[4]  M. Russo,et al.  Down‐regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells , 2009, Journal of cellular physiology.

[5]  L. Koniaris,et al.  Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. , 2009, The Journal of bone and joint surgery. American volume.

[6]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[7]  K. S. Hall,et al.  Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience , 2009, Acta oncologica.

[8]  S. Ferrari,et al.  High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions , 2008, Journal of surgical oncology.

[9]  E. Itoi,et al.  Sex steroid receptors expression and hormone‐induced cell proliferation in human osteosarcoma , 2008, Cancer science.

[10]  J. Brooks,et al.  Immunohistochemical Expression of Estrogen Receptors in Chondrosarcomas and Enchondromas , 2008, International journal of surgical pathology.

[11]  A. Stewart,et al.  Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma: National Cancer Data Base Report , 2007, Clinical orthopaedics and related research.

[12]  S. Gapstur,et al.  Cancer Epidemiology and Prevention, 3rd Edition , 2007 .

[13]  R. Hoover,et al.  Perinatal factors, growth and development, and osteosarcoma risk , 2006, British Journal of Cancer.

[14]  S. Ferrari,et al.  Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Cleton-Jansen,et al.  Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma , 2005, Clinical Cancer Research.

[16]  A. Cleton-Jansen,et al.  Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. , 2005, The Lancet. Oncology.

[17]  William D Mosher,et al.  Use of contraception and use of family planning services in the United States: 1982-2002. , 2004, Advance data.

[18]  M. Alini,et al.  Action of Estradiol on Epiphyseal Growth Plate Chondrocytes , 2004, Calcified Tissue International.

[19]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[20]  T. Murray Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. , 1998, Survey of ophthalmology.

[21]  Ø. Bruland,et al.  On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. , 1997, European journal of cancer.

[22]  J. Madans,et al.  Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. , 1997, American journal of epidemiology.

[23]  S. Tretli,et al.  Lifestyle changes during adolescence and risk of breast cancer: an ecologic study of the effect of World War II in Norway , 1996, Cancer Causes & Control.

[24]  H. Adami,et al.  Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. , 1996, Journal of the National Cancer Institute.

[25]  H. B. Marsden,et al.  Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. , 1996, Journal of the National Cancer Institute.

[26]  T. Fears,et al.  Graphical presentation of trends in rates. , 1995, American journal of epidemiology.

[27]  T. Holford Analysing the temporal effects of age, period and cohort , 1992, Statistical methods in medical research.

[28]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[29]  F. Sim,et al.  Survival and management considerations in postirradiation osteosarcoma and Paget's osteosarcoma. , 1991, Clinical orthopaedics and related research.

[30]  A. Polednak Primary bone cancer incidence in black and white residents of New York state , 1985, Cancer.

[31]  T R Holford,et al.  The estimation of age, period and cohort effects for vital rates. , 1983, Biometrics.

[32]  D. Isenberg,et al.  Osteosarcoma complicating familial Paget's disease. , 1980, Postgraduate medical journal.

[33]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[34]  G. Ardran,et al.  Radiographic features of bone in several strains of laboratory mice and of their tumours induced by bone-seeking radionuclides. , 1976, Journal of anatomy.

[35]  C. Beauchamp Ewing Sarcoma Demonstrates Racial Disparities in Incidence-related and Sex-related Differences in Outcome: An Analysis of 1631 Cases From the SEER Database, 1973-2005 , 2010 .

[36]  G. Ottaviani,et al.  The etiology of osteosarcoma. , 2009, Cancer treatment and research.

[37]  J. Moppett,et al.  Second malignancies in children: the usual suspects? , 2001, European journal of radiology.

[38]  G COOPER,et al.  Bone cancer. , 1951, Virginia medical monthly.